Investing carries serious risks, including partial or total loss of capital. Please read the Key Investment Information Sheet and the Risk factors and login before investing.
YNIOS Pharma 3A
€56,000
total amount raised in round
6 days
remaining
- Eligible for a tax reduction
MARKET
- SEPTIC SHOCK MARKET
Each year, Septic Shock affects more than 30 million people worldwide and is one of the leading causes of death among critically ill patients globally.
The market for systemic inflammatory response syndrome treatment is led by the United States, followed by Europe and the Asia-Pacific region.
Given that the inflammatory process of Septic Shock is present in multiple conditions (AIS, MI, etc.), the market potential is significant. According to a report by Precedence Research, the Septic Shock treatment market is expected to grow from USD 10.49 billion to USD 21.36 billion between 2020 and 2030 (CAGR of 8%). The intensive care market, including Septic Shock, acute ischemic stroke, and acute myocardial infarction, is estimated at USD 54 billion.
- KIDNEY TRANSPLANT MARKET
The global market revenue for organ transplant rejection drugs is expected to reach USD 7.4 billion by 2032, with a CAGR of 3.4% between 2023 and 2032.
The key drivers of the organ transplant rejection drug market include the increasing demand from patients, technological advancements, and evolving consumer preferences towards health and well-being.
In 2022, North America dominated with 43% of the market share for transplant rejection drugs. The Asia-Pacific market is expected to grow, with an estimated CAGR of about 3.9% from 2023 to 2032.
The major players include Pfizer, Inc., Astellas Pharma, Inc., Novartis AG, and F. Hoffmann-La Roche Ltd.
TAX SHELTER 45%
Investments in this company benefit from a 45% personal income tax reduction. Read more…A remaining amount of €25,400 is available for the Tax Shelter benefit.
Fact sheet
| Advised by a professional start-up advisor | |
| Valuation is set by the co-investor or incubator | |
| Co-investor or incubator will be members or observers to the board | |
| At the closing, an incubator, accelerator, or studio will have shares | |
| At the closing, the entrepreneurs have contributed a minimum of €15,000 in cash in exchange for shares | |
| Raised €10,000 during a private phase | |
| At the closing, a professional co-investor will have invested at least €25,000 | |
| Prior fundraising in equity or convertible loan with 10 or more investors | |
| Seasoned entrepreneurs | |
| Minimum 2 active entrepreneurs | |
| Valuation set by an organisation specialized in valuations of comparable size | |
| Valuation is less than €1 million or 10x last year’s turnover |
Raise summary
| Crowd investments | €56,000 |
| Committed by others | €0 |
| Amount raised | €56,000 |
| Minimum round | €25,000 |
| Maximum round | €300,000 |
| Shares in the company (total round) | 4.773% |
| Pre-money valuation | €5,985,300 |
| Post-money valuation min. | €6,010,300 |
| Post-money valuation max. | €6,285,300 |